Press Releases

Manhattan Scientifics, Inc. Announces Stock Repurchase Program

(August 26, 2015) NEW YORK--Manhattan Scientifics, Inc. ("Manhattan Scientifics”), (OTCQB:MHTX) announced that it is initiating a share repurchase program. Manhattan Scientifics' Board of Directors designated a program to repurchase, from time to time, at management's discretion, shares of the Company's common stock with a value of up to $500,000 in the open market at prevailing market prices over the next 12 months. Full release

MHTX Announces Issuance of Additional Patent Covering Detection and Imaging of Cancer Cells

(August 10, 2015) NEW YORK--Manhattan Scientifics, Inc. announced today that its Senior Scientific, LLC unit, a nanobiotechnology company for the early detection and localization of cancer and other human diseases, has been granted an additional United States Patent for its MRX™ cancer detection technology. Full release

Manhattan Scientifics Engages Services of Torreya Partners

(July 16, 2015) NEW YORK--Manhattan Scientifics, Inc. today announced the engagement of Torreya Partners and its professional services sister company, Torreya Insights. Full release

A Letter from the New President of Senior Scientific LLC

(May 7, 2015) Cancer continues to be one of the leading causes of mortality globally. Despite technical advances in science and medicine made in the last 150 years we still lack effective forms of therapy for many types of cancer, and the general consensus within the medical community is that more lives could be saved if cancer could be detected earlier. Full release

Letter to Shareholders

(April 20, 2015) Manhattan Scientifics, Inc. owns and is commercializing two nanotechnology businesses: nanostructured metals through our Metallicum subsidiary, and nanotechnology for the very early detection of cancers through our Senior Scientific subsidiary. The past year has been an important one for Manhattan Scientifics with a number of notable achievements. Full release

Manhattan Scientifics Announces Return of Marvin Maslow as Chairman of the Board

(March 25, 2015) NEW YORK--Manhattan Scientifics, Inc. announced today that Marvin Maslow, founder of MSI, has re-joined the Company’s Board of Directors as Chairman. Full release

MHTX to Immediately Receive $8M as it Reacquires its Nano-Structured Metals Tech & Related IP

(February 18, 2015) NEW YORK--Manhattan Scientifics, Inc. has reacquired all rights in its nano-structured metals technology from its former Licensee whose strategic corporate priorities had changed. The agreement includes a one-time payment to Manhattan of $8 million, the assignment to Manhattan of all related IP and the transfer of ownership of various ECAP machinery and equipment used in the manufacturing process of nano-structured metals. Full release

MHTX Recruits Robert R. Proulx as New President and COO for Its Senior Scientific Subsidiary

(January 14, 2015) ALBUQUERQUE, N.M.--Manhattan Scientifics, Inc. has recruited Robert R. Proulx (pronounced “Pru”) to the position of President and Chief Operating Officer of its Senior Scientific LLC subsidiary, effective January 12. Full release

Manhattan Scientifics Announces Expansion of Executive Team at Its Senior Scientific Subsidiary

(December 30, 2014) ALBUQUERQUE, N.M.--Manhattan Scientifics, Inc. is recruiting a seasoned executive to oversee Senior Scientific’s next stage of product development for its MRX diagnostic technology for the early detection of cancer. Full release

Manhattan Scientifics Completes $2.0 Million Equity Raise

(November 21, 2014) ALBUQUERQUE, N.M.--Manhattan Scientifics, Inc. has completed a $2.0 million equity raise. Details of the raise are available in the Company’s November 18th 8K filing with the SEC. The proceeds will primarily be used to fund the advancement, demonstration and validation of its MRX cancer diagnostic technology under development by its subsidiary, Senior Scientific, LLC. Full release

Manhattan Scientifics Engages Dian Griesel Int’l.

(October 30, 2014) NEW YORK--Manhattan Scientifics, Inc. (OTCQB: MHTX) has engaged Dian Griesel Int’l. (DGI) to manage media relations. DGI will work toward the objective of increasing awareness of the company and its subsidiary Senior Scientific LLC, which has developed and patented technologies that use bio safe nanoparticles and sensitive magnetic sensors to detect and measure cancer cells more rapidly and less expensively than current methods. Full release

MHTX’s Unparalleled Cancer Measurement Technology Featured in MD Anderson Presentation

(October 8, 2014) ALBUQUERQUE, N.M.--Senior Scientific LLC, a subsidiary of Manhattan Scientifics, Inc. (OTCQB: MHTX), is currently collaborating with The University of Texas MD Anderson Cancer Center (MDACC) to advance, demonstrate and validate a cancer detection and measurement technology originally developed by Edward R. Flynn, PhD. John D. Hazle, PhD of the MD Anderson Cancer Center. Full release

MHTX Issues Follow Up Report to Shareholders - “Pushing the Limits of Cancer Detection”

(October 2, 2014) ALBUQUERQUE, N.M. – Three months ago Manhattan Scientifics (OTCQB: MHTX) announced the delivery of its 1st breakthrough cancer measurement instrument to M.D. Anderson Cancer Center in Houston. The Company's technology uses iron oxide nanoparticles and a technique it calls Magnetic Relaxometry to locate and measure cancers with a sensitivity that would provide a diagnosis years before other known methods.  Full release

Manhattan Scientifics Reaches the Fork (Falk) in the Road

(August 20, 2014) ALBUQUERQUE, N.M.--Spencer Falk, whose marketing expertise was mission-critical to the blockbuster success of Viagra and Celebrex, among other medical brands, today announced that he would lead the commercialization of early cancer detection technology for Senior Scientific, a division of Manhattan Scientifics. Full release

Pushing the Limits of Cancer Detection

(June 10, 2014) ALBUQUERQUE, N.M.-- Manhattan Scientifics, Inc. (OTCQB: MHTX) announced today that it has delivered its break-through, cancer measurement instrument to The University of Texas M.D. Anderson Cancer Center in Houston, TX. Full release

PrecisionMRX™ Nanoparticle Production Process Ready

(April 14, 2014) Building upon local relationships, Senior Scientific is stepping into the commercial space with first product introductions through Azano Biotech. Azano currently supplies research reagents to the same cancer researchers who will eventually be customers for the MRX II instrument. Full release

Progress on our First Major Product: the NanoMRX™ II

(March 19, 2014) The overarching mission for February has been to get the 9 Channel System up and running. We are delighted to be delivering this extraordinary device to our collaborators at MD Anderson. Full release

Manhattan Scientifics Announces Commercial Introduction Of NanoMRX Precision Nanoparticles

(March 18, 2014) ALBUQUERQUE, N.M. -- Manhattan Scientifics (OTCQB: MHTX) announced today a collaboration with Azano Biotech that will make NanoMRX Precision Nanoparticles available for purchase. Full release

MHTX Announces Collaboration with MD Anderson Cancer Center

(January 27, 2014) ALBUQUERQUE, N.M.--Manhattan Scientifics (OTC: MHTX) executed an agreement to collaborate with The University of Texas MD Anderson Cancer Center (MDACC) to advance, demonstrate and validate a breakthrough technology developed by Edward R. Flynn, PhD, for the very early detection of cancer. Dr. Flynn is the founder and chief scientist of MHTX’s subsidiary, Senior Scientific LLC. Senior Scientific is seeking to commercialize this patented non-invasive technology using ultra-sensitive magnetic detectors to locate, identify and measure tumors thousands of times smaller than detectable using current technologies. Full release

MHTX Announces Initiation of Coverage by Independent Equity Research Firm SeeThruEquity, LLC

(October 1, 2013) New York, NY – Manhattan Scientifics Inc. (OTCQB: MHTX) announced today that SeeThruEquity, LLC has initiated coverage on the Company. The report is now available for viewing at the following link.  Full release

MHTX Announces the Engagement of Loraine Upham to Market Its Cancer Diagnostic Technology

(August 23, 2013) Manhattan Scientifics announced today that Loraine Upham has been engaged as a consultant to support its cancer team. The technology, developed by Edward R. Flynn, PhD, provides the most specific and most sensitive method for detecting cancer currently known. Full release

Senior Scientific Announces Issuance of U.S. Patent

(May 23, 2013) Senior Scientific, LLC, a unit of Manhattan Scientifics and a developer of molecular imaging and nanobiotechnology for the early detection and localization of cancer and other human diseases, today announced that the United States Patent Office (USPTO) has issued U.S. Patent No. 8,447,379 entitled "Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof." Full release

Manhattan Scientifics Announces Receipt of $2.5M Commitment to Build Breakthrough Cancer Detection

(April 9, 2013) NEW YORK--Manhattan Scientifics announced today that it has received the initial $1 million of a $2.5 million commitment to build the first generation of its advanced cancer detection devices. Full release

Interview with mobile phone inventor Marty Cooper

(April 3, 2013) The first mobile phone call was made 40 years ago today, on 3 April 1973. Martin Cooper, at the time a senior engineer at Motorola and now a member of our Science and Technology Committee, called a rival colleague at another telecoms company and announced he was speaking from "a 'real' cell telephone". Full release

Past Releases